Marshall Stanton Sells 4,993 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 4,993 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $45.86, for a total value of $228,978.98. Following the transaction, the senior vice president directly owned 56,641 shares in the company, valued at $2,597,556.26. The trade was a 8.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Artivion Trading Up 0.3%

Shares of Artivion stock opened at $45.71 on Friday. The business has a fifty day simple moving average of $42.69 and a two-hundred day simple moving average of $36.27. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $48.04. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of -108.84 and a beta of 1.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. The firm had revenue of $113.39 million for the quarter, compared to the consensus estimate of $110.71 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on AORT shares. Wall Street Zen raised shares of Artivion from a “buy” rating to a “strong-buy” rating in a report on Saturday. Canaccord Genuity Group upped their target price on Artivion from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, November 7th. JMP Securities lifted their price target on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Finally, Stifel Nicolaus increased their price objective on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, September 29th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Artivion presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.11.

Institutional Investors Weigh In On Artivion

Large investors have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd increased its stake in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares during the period. MCF Advisors LLC lifted its position in shares of Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after acquiring an additional 614 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares in the last quarter. State of Wyoming bought a new position in shares of Artivion in the third quarter worth $80,000. Finally, Quadrant Capital Group LLC acquired a new position in Artivion in the third quarter valued at about $92,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.